NDAINJECTIONINJECTABLE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SENSORCAINE is a local anesthetic combination containing bupivacaine hydrochloride and epinephrine bitartrate, administered by injection. It is used for infiltration, nerve block, and epidural anesthesia in surgical and procedural settings. The epinephrine component provides vasoconstriction, extending the duration of anesthetic effect and reducing systemic toxicity.
LOE Approaching
As a mature product approaching loss of exclusivity, the brand team is likely focused on retention strategies and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SENSORCAINE represents a stable but declining career opportunity within a mature, highly competitive market segment. Roles on this product team focus on cost containment, regulatory maintenance, and defending market share rather than innovation or growth.
Regulatory Affairs SpecialistSupply Chain Manager
Worked on SENSORCAINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.